DOCSLIB.ORG

Clinical Research Services

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Research Services Clinical Research Services Advancing the future of medicine through research. Who We Are Experience Clinical Research Services is a department within Clinical Research Services has been involved CHI St. Alexius Health in Bismarck, ND. We are fully in clinical research since 1987. Our professional dedicated to providing research support services staff has more than 180 years of combined to physicians within our region and the valued experience in clinical trials. We are committed patients they serve. to providing outstanding service to ensure the success of every project. CHI St. Alexius Health is a tertiary care facility affiliated with PrimeCare, a health group which Our involvement in inpatient and outpatient combines the most experienced, trusted, and phase II-IV clinical and device research studies has proven medical leaders in the area. PrimeCare is contributed substantially to the approval of new comprised of a network which includes more than drugs and treatments. You should carefully consider 190 physicians in private and institutional practice, both the benefits and the risks of participation including: CHI St. Alexius Health, Mid Dakota Clinic, before enrolling in a study. The Bone & Joint Center, and other affiliated area physicians. Many of these physicians are actively Previous clinical study trials: involved as investigators for clinical trials. • Oncology • Orthopaedic • Rheumatology • Diabetes Our clinical research team is committed to providing: • Neurology • Weight loss • Rapid study start-up • Cardiology • Pain • Pro-active patient enrollment • Urology • Men’s Health • Clean data submission • Gastroenterology • Women’s Health • Highly experienced principal • Infectious Disease • Medical Devices investigators • Pediatric • Initial training and continuing education for all support personnel Sponsors Patient Demographics Abbott Laboratories Characteristics of our patients include Acorda Therapeutics, Inc. Alba Therapeutics Corporation prominent northern European and Native Alcon Research, Ltd. American populations with a low drop-out rate. Amgen, Inc. Arena Pharmaceuticals, Inc. Our service area encompasses central and AstraZeneca Pharmaceuticals LP western North Dakota, northern South Dakota Bayer HealthCare and eastern Montana. This area is made up Biogen Idec Boehringer Ingelheim of a population of approximately 400,000 Boston Scientific individuals. Bristol-Myers Squibb Company Cell Therapeutics, Inc. Cephalon, Inc. Facility Description Crosstrees Medical, Inc. As a department within CHI St. Alexius Health Cubist Pharmaceuticals Depomed, Inc. Clinical Research Services is centered among DePuy Spine, Inc.(Johnson & Johnson Company) CHI St. Alexius Health multi-specialty clinics. Eli Lily & Co. ev3 Inc. The 306-medical center is equipped with Forest Laboratories Institute, Inc. CT, PET scan, MRI, Hologic DEXA scanners, Genentech, Inc. GlaxoSmithKline a state-of-the-art radiotherapy Cancer Care Hoffman-La Roche Inc. Center, an accredited sleep laboratory, an Hologic, Inc. outpatient hemodialysis and peritoneal Incyte Corporation Inspire Pharmaceuticals, Inc. dialysis center, and regional laboratory Janssen Pharmaceuticals (Johnson & Johnson Company) services. It also offers full electrophysiologic Javelin Pharmaceuticals, Inc. and interventional cardiology labs. Johnson & Johnson KV Pharmaceutical Company Luitpold Pharmaceuticals, Inc. Merck & Co., Inc & Merck KgaA Millennium Pharmaceuticals, Inc. Neurocrine Biosciences, Inc. Novartis Pharmaceuticals Corporation Novo Nordisk Nymox Corporation OSI Pharmaceuticals, Inc. Oncothyreon Pfizer Inc. Procter & Gamble QuatRx Pharmaceuticals Roche Laboratories Sanofi-aventis Schwarz Biosciences, Inc. SHIRE SkyePharma Takeda Pharmaceutical Company Limited Vivus, Inc. Our Objective The objective of Clinical Research Services is to advance the future of medicine by providing research opportunities for participants, physicians, our community and sponsor organizations. Our comprehensive clinical expertise, innovative approach and high quality are demonstrated by fostering relationships through integrity, teamwork and excellent customer service. Clinical Research Services 1310 East Main Avenue, Suite 203 Bismarck, ND 58501 Phone: (701) 530-6950 • (877) 701-6677 Fax: (701) 530-6970 • web: st.alexius.org.
Load more

Recommended publications
  • OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration
    OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration July 21, 2009 9:24 PM ET MELVILLE, NY and CAMBRIDGE, Mass., July 21, 2009 – OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) and AVEO Pharmaceuticals, Inc. today announced that they have expanded the drug discovery and translational research collaboration announced in October of 2007. The alliance is anchored around developing molecular targeted therapies to target the underlying mechanisms of epithelial-mesenchymal transition (EMT) in cancer and to develop proprietary datasets of associated patient selection biomarkers to support OSI’s targeted medicine pipeline. EMT is a process of emerging significance in tumor development and disease progression and the focal point of OSI’s proprietary oncology research efforts. The companies are expanding their efforts to validate cancer targets and to deploy key elements of AVEO’s proprietary translational research platform in support of OSI’s clinical development programs. Under the terms of the expanded discovery and research agreement, OSI will pay AVEO a total of $20 million at closing, $5 million of which is an upfront cash payment and $15 million of which is the purchase of additional equity in AVEO. OSI will also provide AVEO research funding over the next two years to support the collaboration, and the potential to achieve additional royalties and milestones. In return, OSI will immediately receive rights beyond the original collaboration including rights to additional EMT targets (including up to 4 antibody targets) and increased access to AVEO technology (i.e. tumor models, archives and biomarkers). OSI is also acquiring non-exclusive access to AVEO’s proprietary bioinformatics platform.
    [Show full text]
  • 9894 Pharma Tech Media Planner V6 2007
    www.pharmtech.com years 1977– 2007 30ANNIVERSARY CELEBRATING 30 YEARS AS THE 2007 INDUSTRY’S MOST AUTHORITATIVE SOURCE Media Planner years 1977–2007 ANNIVERSARY years 1977–2007 ANNIVERSARY THE PHARMACEUTICAL TECHNOLOGY BRAND PUBLISHER’S STATEMENT Pharmaceutical Technology’s authoritative reputation and powerful brand recognition within the pharmaceutical/biopharmaceutical development & manufacturing marketplace will help you establish and maintain your own strong brand among pharma industry decision makers. A circulation of 38,667 BPA-qualified subscribers* and unmatched peer written and reviewed editorial make Pharmaceutical Technology an invaluable resource within top pharma companies, as well as small, specialty and biotech pharma companies spending billions each year on pharmaceutical development and manufacturing. Please celebrate with us as Pharmaceutical Technology marks its 30th Anniversary as the industry leader. —Michael Tracey, Publisher % 90 of readers rated Pharmaceutical Technology as important or very important to them as a professionalˆ EDITORIAL MISSION Pharmaceutical Technology publishes authoritative, reliable, and timely peer-reviewed research and expert analyses for scientists, engineers, technicians, and managers engaged in process development, manufacturing, formulation, analytical technology, packaging and regulatory compliance in the pharmaceutical and biotechnology industries. —Douglas McCormick, Editor in chief www.pharmtech.com *BPA June 2006 Statement ^2006 Readership Study Conducted by Advanstar Research
    [Show full text]
  • IPR2016-01284 Patent 6,900,221 B1 ______
    [email protected] Paper No. 49 571.272.7822 Filed: January 8, 2018 UNITED STATES PATENT AND TRADEMARK OFFICE ____________________ BEFORE THE PATENT TRIAL AND APPEAL BOARD ____________________ APOTEX INC., APOTEX CORP., APOTEX PHARMACEUTICALS HOLDINGS INC., AND APOTEX HOLDINGS, INC., Petitioner, v. OSI PHARMACEUTICALS LLC, Patent Owner. ____________________ Case IPR2016-01284 Patent 6,900,221 B1 ____________ Before LORA M. GREEN, RAMA G. ELLURU, and ZHENYU YANG, Administrative Patent Judges. GREEN, Administrative Patent Judge. FINAL WRITTEN DECISION Determining That Claims 44‒46 and 53 Are Shown to Be Unpatentable 35 U.S.C. § 318(a) and 37 C.F.R. § 42.73 IPR2016-01284 Patent 6,900,221 B1 I. INTRODUCTION Apotex Inc., Apotex Corp., Apotex Pharmaceuticals Holdings Inc., and Apotex Holdings, Inc., (“Apotex” or “Petitioner”) filed a Petition requesting an inter partes review of claims 44–47 and 53 of U.S. Patent No. 6,900,221 B1 (Ex. 1001, “the ’221 patent”). Paper 3 (“Pet.”). OSI Pharmaceuticals LLC1 (“OSI” or “Patent Owner”) filed a Preliminary Response to the Petition.2 Paper 7 (“Prelim. Resp.”). We determined that the information presented in the Petition and the Preliminary Response demonstrated that there was a reasonable likelihood that Petitioner would prevail in challenging claims 44–47 and 53 as unpatentable under 35 U.S.C. § 103(a). Pursuant to 35 U.S.C. § 314, we instituted trial on January 9, 2017, as to all of the challenged claims of the ’221 patent. Paper 8 (“Institution Decision” or “Dec. Inst.”). On February 8, 2017, the parties filed a Joint Motion to Limit Petition Under 37 C.F.R.
    [Show full text]
  • Manufacturers with Signed Rebate Agreements February 1 , 2011
    Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements February 1 , 2011 NEWLABELER NAME START END SC NEW LABELER NAME START END SC 00002 ELI LILLY AND COMPANY 1/1/1991 Y 00126 COLGATE ORAL PHARMACEUTICAL 1/1/1991 Y 00003 E R SQUIBB AND SONS INC. 1/1/1991 Y 00131 SCHWARZ PHARMA, INC. 1/1/1991 Y 00004 HOFFMANN LAROCHE INC 1/1/1991 00132 C B FLEET COMPANY INC. 1/1/1991 00005 LEDERLE LABORATORIES 1/1/1991 Y 00135 SMITHKLINE BEECHAM 1/1/1995 Y 00006 MERCK SHARP & DOHME 1/1/1991 Y 00143 WEST-WARD PHARMACEUTICAL C 1/1/1991 Y 00007 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00145 STIEFEL LABORATORIES INC. 1/1/1991 Y 00008 WYETH AYERST LABORATORIES 1/1/1991 Y 00149 PROCTER & GAMBLE PHARMACEU 1/1/1991 Y 00009 PHARMACIA AND UPJOHN 1/1/1991 Y 00168 E FOUGERA AND CO, DIV OF ALTAN 1/1/1991 Y 00013 PHARMACIA AND UPJOHN 1/1/1991 Y 00169 NOVO NORDISK PHARMACEUTICAL 1/1/1991 Y 00015 INVAMED, INC 1/1/1991 Y 00172 ZENITH LABORATORIES, INC 1/1/1991 Y 00023 ALLERGAN INC. 1/1/1991 Y 00173 GLAXOSMITHKLINE 1/1/1991 Y 00024 SANOFI SYNTHELABO 1/1/1991 Y 00178 MISSION PHARMACAL COMPANY 1/1/1991 Y 00025 PHARMACIA CORPORATION 1/1/1991 Y 00182 GOLDLINE LABORATORIES INC 1/1/1991 Y 00026 BAYER CORP PHARMACEUTICAL DI 1/1/1991 Y 00185 EON LABS MANUFACTURING, INC. 1/1/1991 Y 00028 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00186 ASTRAZENECA LP 1/1/1991 Y 00029 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00187 ICN PHARMACEUTICALS INC.
    [Show full text]
  • Reporter's Handbook
    2O14 RE POR TER’ S HANDBOOK for the biopharmaceutical research industry Member Companies 1 Research Associates 2 U.S. Health-Related Trade and Professional Organizations 3 Government Medical and Health Contacts 4 Voluntary Health Agencies 5 International Pharmaceutical Associations/Health Care Groups 6 Key Facts/About PhRMA 7 Company Products by Category 8 Member Companies 1 Member Companies Abbott Dept 383, AP6D 100 Abbott Park Road Abbott Park, IL 60064-3500 Phone: (847) 937-6100 Fax: (847) 937-1511 Website: www.abbott.com Melissa Brotz, Corporate Public Affairs Office: (847) 935-3456 E-Mail: [email protected] Kelly Morrison, Corporate Public Affairs, Science/Policy Office: (847) 937-3802 E-Mail: [email protected] Scott Stoffel, Corporate Public Affairs, Financial Office: (847) 936-9502 E-Mail: [email protected] Steve Chesterman, Medical Optics Office: (714) 247-8711 E-Mail: [email protected] Jonathon Hamilton, Vascular Devices 3200 Lakeside Drive, Suite 355 Santa Clara, CA 95054 Office: (408) 845-3491 E-Mail: [email protected] AbbVie 1 North Waukegan Road North Chicago, IL 60064 Phone: (847) 932-7900 Website: www.abbvie.com Gulden Mesara, Vice President, Global Commercial and Health Communications Office: (847) 938-2804 E-Mail: [email protected] Angela Sekston, Vice President, Leadership and Employee Communications Office: (847) 937-6636 E-Mail: [email protected] Morry Smulevitz, Head of U.S. Public Affairs Office: (847) 937-2152 E-Mail: [email protected] 1-1
    [Show full text]
  • In the United States District Court for the District of Delaware
    Case 1:15-cv-01063-UNA Document 1 Filed 11/17/15 Page 1 of 17 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE OSI PHARMACEUTICALS, LLC, PFIZER ) INC., and GENENTECH, INC., ) ) Plaintiffs, ) ) v. ) C.A. No. ) BRECKENRIDGE PHARMACEUTICAL, ) INC. and NATCO PHARMA LTD., ) ) Defendants. ) COMPLAINT FOR PATENT INFRINGEMENT Plaintiffs OSI Pharmaceuticals, LLC (“OSI”), Pfizer Inc. (“Pfizer”) and Genentech, Inc. (“Genentech”) (collectively, “Plaintiffs”), by their undersigned attorneys, bring this action against Defendant Breckenridge Pharmaceutical Inc., (“Breckenridge”), and Natco Pharma Ltd. (“Natco”) (collectively, “Breckenridge/Natco”) for patent infringement and allege as follows: NATURE OF THE ACTION 1. This is an action for patent infringement under the patent laws of the United States, Title 35 of the United States Code, the Federal Food, Drug, and Cosmetic Act, Title 21 of the United States Code, and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 et seq., arising from Breckenridge/Natco’s filing of an Abbreviated New Drug Application No. 208488 (“Breckenridge/Natco ANDA” or “ANDA No. 208488”) with the United States Food and Drug Administration (“FDA”) seeking approval to commercially market generic versions of TARCEVA® (“Breckenridge/Natco’s Proposed Generic Products”) prior to the expiration of certain patents that relate to that product, United States Reissued Patent No. RE 41,065 (“the RE ‘065 patent”), and United States Patent No. 6,900,221 (“the ‘221 patent”). Case 1:15-cv-01063-UNA Document 1 Filed 11/17/15 Page 2 of 17 PageID #: 2 THE PARTIES 2. Plaintiff OSI is a limited liability company organized and existing under the laws of the State of Delaware, with a principal place of business at 1 Astellas Way, Northbrook, IL 60062.
    [Show full text]
  • Representative Healthcare and Life Sciences M&A Transactions
    Representative Healthcare and Life Sciences M&A Transactions • Medtronic plc. Representing Medtronic plc in its $458 million acquisition of Twelve, Inc., a developer of devices for the treatment of chronic cardiovascular diseases. • Shire plc. Representing Shire plc in its $30 billion acquisition of Baxalta Incorporated, a developer of products for the treatment of hematology and immunology worldwide. • Pfizer Inc. Representing Pfizer Inc. in its $130 million acquisition of GlaxoSmithKline plc, a UK-based pharmaceuticals company. • Pfizer Inc. Representing Pfizer Inc. in its $17 billion acquisition of Hospira Inc., a provider of injectable drugs and infusion technologies. • Wright Medical Group. Representing Wright Medical Group in its $3.3 billion merger of equals with Tornier N.V., a Netherlands-based medical device company. • Synageva BioPharma. Represented Synageva BioPharma in its $8 billion sale to Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. • Pfizer Inc. Represented Pfizer Inc. in its investment in AM-Pharma B.V., an Amsterdam-based biopharmaceutical company. • Becton, Dickinson & Company. Represented Becton, Dickinson & Company in its acquisition of CRISI Medical Systems, Inc., a medical device company, focuses on the development of drug-delivery systems. • Cubist Pharmaceuticals. Represented Cubist Pharmaceuticals in its $9 billion sale to Merck & Co. Inc., a provider of health care solutions worldwide. • Symmetry Medical. Represented Symmetry Medical Inc. In the sale of OEM Solutions business to Tecomet, a Genstar Capital portfolio company, for $450 million. As part of the deal, Symmetry, a publicly held medical device solutions provider, will also spin off and transfer to its shareholders ownership in a new company, Specialty Surgical Instruments.
    [Show full text]
  • Memorandum JUL 1 6 201D
    Memorandum Subject Date Additional Quota Letters Received by July 15, 2010 (DFN: 630-08.2) JUL 1 6 201D To From Christine A. Sanncrud. Ph.D., Chief "Barbar• J.Illoockholdt, Chief Drug & Chemical Evaluation Section Regul• torn Section Office of Diverison Control Off cL rl Diversion Control On July 15. 2010, this section received your e-mail requesting a review of seventeen (17) quota applications from sixteen (16) registered manufacturers to determine if there arc any pending administrative/legal actions against these applicants and to advise ODE of the findings. ODOR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations. QUOTA APPLICANTS wan NO ADVERSE OR DEROGATORY INFORMATIO N Novartis Consumer I lealth Lincoln (10345) (b)(4);(b)(7)(E) Baxter (10346) Generics Bidco li bda Vintage (10347) Noramco Delaware (10348) Pharmaceuticals International inc. (10349) Pharmedium (10351) Pharmedium (10352) Rhodes (10356) Bio-Pharm (10357) Patheon (10358) Patheon (10359) Watson (10361) B & B (10363) lospira. Inc. NC (10364) Epic Pharma (10366) Mallinckrodt I lobart (10367) Chemtos (10368) Vol. II Page 55 2 Per consultation with the field offices. DEA does not have sufficient grounds to limit, restrict. or deny quota requests from these registrants. Based on this information. ODG suggests that you proceed with the completion of the quota applications. If you have any questions pertaining to this information. please feel free to contact me (b)(6);(b)(7)( or SC C) (b)(6);(b)(7)(C) Vol. II Page 56 Memorandum Subject Date Additional Quota Letters Received as of July 19, 201() (DFN: 630-08.2) stir 2 8 2010,., To Fr ,./"./ Christine A.
    [Show full text]
  • Major Employers of Chemists in the Northeastern Section
    Major Employers of Chemists in the Northeastern Section by Don Rickter with valuable assistance from Karen Piper, Mike Filosa, Lee Johnson, Dorothy Phillips and others Eastern Massachusetts and New Hampshire are a hotbed of dynamic chemistry companies. Some are start-ups that will grow dramatically. There are dozens of companies in both states. Some will merge or be acquired or change their names. Each has a unique personality and spectrum of expertise. The following list is most of the employers of seven or more members of the American Chemical Society — as of the end of May 2010. A few of the larger employers, with more than 35 ACS chemists, are in ALL CAPS. The locations are in eastern Massachusetts — unless marked with NH for New Hampshire. Aerodyne Research BIOGEN IDEC Cubist Pharmaceuticals Billerica CAMBRIDGE Lexington www.aerodyne.com/ www.biogenidec.com/ www.cubist.com Alkermes Inc. Boston Scientific Corp. Dow Electronic Materials Waltham Natick Marlborough www.alkermes.com/ www.bostonscientific.com/ www.dow.com/ & home.bsci www.rohmhaas.com/ Alnylam Pharmaceuticals Broad Institute [rhymes DSM-Neoresins Cambridge with road] Cambridge Wilmington www.alnylam.com/ www.broadinstitute.org/ www.dsm.com/en_US/htm l/dnr/home. htm AMGEN INC. Bruker Corp. CAMBRIDGE Billerica www.bruker.com E-Ink Corp. www.amgen.com/ Cambridge www.e- Cabot Corp. ink.com Ariad Pharmaceuticals Billerica www.cabot- Cambridge corp.com EISAI RESEARCH www.ariad.com/ INSTITUTE Cambridge Isotope Labs ANDOVER Arqule Inc. Andover www.easai.com Woburn www.arqule.com/ www.isotope.com/ EMD Serono ASTRA ZENECA Concert Pharmaceuticals Rockland WALTHAM Lexington www.emdserono.com www.astrazeneca.com/ www.concertpharma.com Enanta Pharmaceuticals Microbia (Also see Physical Sciences Inc.
    [Show full text]
  • 17TH ANNUAL PHARMACEUTICAL and MEDICAL DEVICE COMPLIANCE CONGRESS Office of Inspector General Update
    17TH ANNUAL PHARMACEUTICAL AND MEDICAL DEVICE COMPLIANCE CONGRESS Office of Inspector General Update Mary E. Riordan, Senior Counsel Office of Counsel to the Inspector General October 19, 2016 AGENDA FOR TODAY Update on recent enforcement activity Update on OIG reports and other publications Lessons/suggestions for consideration ISSUES IN RECENT SETTLEMENTS Settlements addressed a variety of areas: Kickback issues Marketing and sales issues Medicaid drug rebate program issues Drug price reporting issues FALSE CLAIM ACT SETTLEMENTS Kickback-related settlements Salix Pharmaceuticals, Inc. Olympus Corporation of the Americas Novartis Pharmaceuticals Warner Chilcott Omnicare, Inc. FALSE CLAIM ACT SETTLEMENTS Settlements involving sales and marketing issues Acclarent, Inc. Genentech Inc. and OSI Pharmaceuticals LLC Paradigm Spine Qualitest Pharmaceuticals Settlement involving Medicaid drug rebate issues Wyeth/Pfizer Settlements involving other issues Imported and compounded drugs CIVIL MONETARY PENALTY SETTLEMENTS Drug Price Reporting CMP Settlements Nephron Pharmaceuticals Corporation Cipher Pharmaceuticals US, LLC Coloplast Corp. OIG REPORTS Drug pricing issues “Average Manufacturer Prices Increased Faster Than Inflation for Many Generic Drugs” – December 2015 (A-06-15-00030) 340B program issues “Part B Payment for 340B Purchased Drugs” - Nov. 2015 (OEI-12-14-00030) “State Efforts to Exclude 340B drugs from Medicaid Managed Care Rebates” – June 2016 (OEI-05-14- 00430) OIG REPORTS Reports relating to the Medicaid
    [Show full text]
  • Oncology Pharmaceutical
    Quarterly Industry Update As of December 31, 2015 Industry: Oncology Pharmaceutical Industry Summary Cogent Valuation identified Oncology Pharmaceutical publicly traded companies, IPOs, and recent M&A transactions within the Oncology Pharmaceutical industry, which provides a basis for market and transaction pricing that can be used by your firm in estimating market sentiment and its impact on your firm's value. Over the last year since December 31, 2014, the median 52-week share price return of the Oncology Pharmaceutical industry was 5.0%. Between December 31, 2013 and December 31, 2015, the median EV/EBITDA multiple decreased from 15.6 to 13.2. However, the median price-to-earnings multiple increased from 21.5 to 23.0 over the same period. Comparable Public Company Key Statistics Median 52-Week Return5.0% Median EV/Revenue Multiple5.0x Median Price/Earnings Multiple 23.0x Median 3-Year CAGR Return26.7% Median EV/EBITDA Multiple13.2x Median EV/Gross CF Multiple 13.2x Comparable Public Company Market Price Returns As of December 31, 2015 YTD 3 Month 1 Year 2 Year 3 Year 5 Year 2015 2014 2013 2012 2011 Affimed N.V. 14.8% 15.4% 14.8% N/A N/A N/A 14.8% N/A N/A N/A N/A Ariad Pharmaceuticals Inc. -9.0% 7.0% -9.0% -4.3% -31.2% 4.2% -9.0% 0.7% -64.4% 56.6% 140.2% Bellicum Pharmaceuticals, Inc. -12.0% 39.5% -12.0% N/A N/A N/A -12.0% N/A N/A N/A N/A Calithera Biosciences, Inc.
    [Show full text]
  • Pharmaceutical Research and Manufacturers of America – Phrma
    The Short-Term and Long-Term Competitive Impact of Authorized Generics A Report for the Federal Trade Commission October 28, 2009 TABLE OF CONTENTS INTRODUCTION ........................................................................................................................... 1 DISCUSSION .................................................................................................................................. 3 I. LONG-TERM COMPETITIVE HARM IS UNLIKELY ................................................... 3 A. Unsupported Foreclosure Claims Have Been Made For Nearly Two Decades .................................................................................................................... 4 B. Marketplace Realities Undercut The Long-Tenn Foreclosure Theory .................... 7 1. Sales and Profitability Are Growing ........................................................... 7 2. Wall Street Valuations Are Growing ........................................................ 10 II. THE FTC PRICING ANALYSIS SHOWS $880 MILLION IN CONSUMER SAVINGS .......................................................................................................................... 14 III. CONSUMER SAVINGS SHOULD BE MEASURED USING WHOLESALE DATA AND WEIGHTED AVERAGE PRICES .............................................................. 17 A. The Wholesale Data Carries Far More Weight.. .................................................... 17 B. Average Drug Prices Should Be Volume-Weighted ............................................. 19 IV.
    [Show full text]